CSE:HUGE NASDAQ:HUGE

FSD Pharma

Market:

CSE

Market Cap:

$50.4 m

Price

2.63 CAD

Change

1.15%

52 weeks high

14.74

52 weeks low

1.70

10.08

Director Interviews

In brief

FSD Pharma Inc. is a publicly-traded holding company, since May 2018.

FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, ultramicronized-palmitoylethanolamide (“FSD201”), by down-regulating the cytokines to effectuate an anti-inflammatory response.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

FSD Pharma throws resources behind legacy anti-inflammatory drug as potential coronavirus therapy

FSD Pharma

Snapshot

The company plans a Phase 2 study of FSD201 in more than 300 COVID-19 patients in October this year

Watch

FSD Pharma - FSD Pharma fully funded to continue progress on its Phase 2 study on coronavirus patients

Director Interviews FSD Pharma fully funded to continue progress on its Phase 2 study on coronavirus patients

on 11/04/2020

FSD Pharma - FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end 2020 as it files IND

Director Interviews FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end 2020 as it files IND

on 09/10/2020

FSD Pharma - FSD Pharma says $10M in new capital is 'gratifying' as the firm makes progress in coronavirus trial

Director Interviews FSD Pharma says $10M in new capital is 'gratifying' as the firm makes progress in coronavirus trial

on 08/10/2020

FSD Pharma - FSD Pharma raises more than C$10M in private placement, makes progress with coronavirus treatment

Director Interviews FSD Pharma raises more than C$10M in private placement, makes progress with coronavirus treatment

on 06/12/2020